Biotech Values

[DewDiligence]

[OT] GTCB:

[From Briefing.Com]:
>>
09:03 ET GTC Biotherapeutics started with a Mkt Outperform at Rodman & Renshaw, tgt $6 (GTCB) 2.45: Rodman & Renshaw initiating coverage on GTC Biotherapeutics with a Market Outperform rating, based on 1) the co's low market valuation, 2) recent filing for approval of its lead drug ATryn in Europe, 3) anticipated initiation of new clinical programs, and 4) steadily improving prospects for transgenic protein therapeutics. The firm thinks the co is attractive at current levels for investors with long-term investment objectives and a high tolerance for risk. Tgt $6.
<<

Not an especially insightful analysis, but this is one of the lowest valuations you will ever see for a company that has a drug application pending in a major jurisdiction.

Glad R&R waited until today because I was still accumulating yesterday.